Our new member Charly8 mentioned this new investigational drug from Gilead GS 9857. It is being combined with Sovaldi and their other investigational drug GS 5816. GS 9857 is a NS 3/4A PI. The data is from Phase 1and 2 studies. They are concentrating on both improved SVR rates and shortened treatment lengths. Keep your eyes open, they just keep coming
Our new member Charly8 mentioned this new investigational drug from Gilead GS 9857. It is being combined with Sovaldi and their other investigational drug GS 5816. GS 9857 is a NS 3/4A PI. The data is from Phase 1and 2 studies. They are concentrating on both improved SVR rates and shortened treatment lengths. Keep your eyes open, they just keep coming
http://www.gilead.com/news/press-releases/2015/4/gilead-announces-data-for-investigational-alloral-pangenotypic-threedrug-regimen-of-sofosbuvir-gs5816-and-gs9857-for-chronic-hepatitis-c